{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T10:45:57Z","timestamp":1792838757879,"version":"4.5.0"},"reference-count":23,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T00:00:00Z","timestamp":1629676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Feline Medicine and Surgery"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Venlafaxine, a specific inhibitor of both noradrenaline and serotonin, is commonly used in human medicine to treat depression, anxiety and social phobia. Its formulation in small granules renders it interesting to test on cats, which are usually reluctant to take medication. Venlafaxine was administered at 1\u2009mg\/kg for 60 days, using a double-blind, placebo-controlled protocol, to cats aged \u2a7e6 months exhibiting aggressiveness, fear or house-soiling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>After one cat\u2019s withdrawal, 21 cats were included in the study: 11 in the venlafaxine group and 10 in the placebo group. Three consultations were conducted, on day 0, day 30 and day 60. Each visit consisted of (1) veterinarian- and owner-based scoring of the cat\u2019s behavioural improvement; (2) scoring of the cat\u2019s compliance with removal from its carrier and compliance with manipulation; and (3) owner scoring of the ease of administration and recording of the potential adverse effects of the treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Improvement was significantly higher in the venlafaxine group; as early as day 30, according to the veterinarian scoring, and at day 60, according to both the veterinarian and owner scoring. In contrast, neither the removal nor the manipulation scores were significantly different between the two treatment groups. Venlafaxine seemed to improve all three studied signs, as early as day 30 for fear and aggressiveness, and at day 60 for house-soiling. The adverse effects of venlafaxine were limited to drowsiness in one cat. All cats tolerated the treatment well during the 60-day period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and relevance<\/jats:title>\n                    <jats:p>These results suggest that venlafaxine is efficient in treating several behavioural problems and is easy to administer. More studies should be conducted to explore its effects at different dosages on specific diagnoses.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1098612x211036792","type":"journal-article","created":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T04:22:26Z","timestamp":1629692546000},"page":"539-549","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":18,"title":["Double-blind, placebo-controlled trial of venlafaxine to treat behavioural disorders in cats: a pilot study"],"prefix":"10.1177","volume":"24","author":[{"given":"Delphine","family":"Metz","sequence":"first","affiliation":[{"name":"Veterinary Clinic of Moulin, Truchtersheim, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiphaine","family":"Medam","sequence":"additional","affiliation":[{"name":"Independent Researcher, Jouques, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6089-5825","authenticated-orcid":false,"given":"Sylvia","family":"Masson","sequence":"additional","affiliation":[{"name":"Clinique v\u00e9t\u00e9rinaire de la Tivolli\u00e8re, Voreppe, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,8,23]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2018.04.033"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cvsm.2017.12.011"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jveb.2007.02.002"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1177\/1098612X15599420"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.2165\/11586630-000000000-00000"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.3109\/00498259409045895"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.3109\/00498259309057023"},{"key":"e_1_3_3_9_2","unstructured":"Taranu A. Identification de biomarqueurs g\u00e9n\u00e9tiques de r\u00e9ponse \u00e0 la Venlafaxine dans une cohorte de patients d\u00e9prim\u00e9s. PhD thesis Universit\u00e9 Paris Sud 2017."},{"key":"e_1_3_3_10_2","unstructured":"Stahl S. Stahl\u2019s essential psychopharmacology. Cambridge: Cambridge University Press 2013."},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0024-3205(02)01848-9"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(00)00622-1"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/vec.12091"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e318192e4c1"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cvsm.2013.04.007"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1748-5827.2009.00908.x"},{"key":"e_1_3_3_17_2","first-page":"13","volume-title":"Proceedings of the American College of Veterinary Behaviorists Annual Symposium","author":"Hopfensperger MJ.","year":"2016","unstructured":"Hopfensperger MJ. Use of oral venlafaxine in cats with feline idiopathic cystitis or behavioral causes of periuria. Proceedings of the American College of Veterinary Behaviorists Annual Symposium; 2016 Aug 5, San Antonio, TX, USA, 2016, pp 13\u201317."},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jveb.2020.10.008"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.5326\/JAAHA-MS-6527"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jveb.2018.03.002"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.beproc.2017.02.008"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0962728600019837"},{"key":"e_1_3_3_23_2","first-page":"18","article-title":"Effects of reconcile (fluoxetine) chewable tablets plus behavior management for canine separation anxiety.","volume":"8","author":"Simpson BS","year":"2007","unstructured":"Simpson BS, Landsberg GM, Reisner IR, et al. Effects of reconcile (fluoxetine) chewable tablets plus behavior management for canine separation anxiety. Vet Ther Res Appl Vet Med 2007; 8: 18\u201331.","journal-title":"Vet Ther Res Appl Vet Med"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.2460\/javma.251.10.1175"}],"container-title":["Journal of Feline Medicine and Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1098612X211036792","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1098612X211036792","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1098612X211036792","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T06:06:28Z","timestamp":1784095588000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1098612X211036792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,23]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["10.1177\/1098612X211036792"],"URL":"https:\/\/doi.org\/10.1177\/1098612x211036792","relation":{},"ISSN":["1098-612X","1532-2750"],"issn-type":[{"value":"1098-612X","type":"print"},{"value":"1532-2750","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,23]]}}}